Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types among Dutch STI Clinic Visitors

Journal of Infectious Diseases

Volumn 217, Issue 2, 2018, Pages 213-222

  Woestenberg, Petra J ^a   King, Audrey J ^a   Van Benthem, Birgit H B ^a   Donken, Robine ^a   Leussink, Suzan ^a,b   Van Der Klis, Fiona R M ^a   De Melker, Hester E ^a   Van Der Sande, Marianne A B ^a,c,d   Hoebe, Christian J P A ^a,e   Bogaards, Johannes A ^a,b   Adema, D ^f   Buist Arkema, R ^f   Beerens, A ^f   Luijt, D ^f   Meijer, S ^f   Schirm, J ^f   Peeters, M ^g   Rossen, J ^g   Verbakel, H ^g   Esch, P Van ^g   Verweij, J ^g   Eijk, A Van Der ^h   Huisman, R ^h   Kerkhof, C ^h   Korff, H ^h   Schutten, M ^h   Velzing, J ^h   Verduyn Lunel, F ^c   Lakbiach, S ^c   Rosmalen, P Van ^c   Schuurman, R ^c   Abma, D ⁱ   Adams, K ⁱ   Bruisten, S ⁱ   Linde, I ⁱ   Oostvogel, P ⁱ   Touwen, C ⁱ   Vermeulen, W ⁱ   Brink, A ^j   Nelissen, J ^j   Wolffs, P ^j   Duijvendijk, N ^k   Schneeberger, P ^k   Poppel, M DInnissen Van ^l   Melchers, W ^l   Poort, Y ^l   Hooghiemstra, M ^m   Huisman, H ^m   Weel, J ^m   Bosma, F ⁿ   Geeraedts, F ⁿ   Polman, I ⁿ   Van Goor, P ^o   Wolfhagen, M ^o   De Mooij, C ^p   Koolwijk, E Van ^p   Peters, M ^p   Swanink, C ^p   Tiemessen, R ^p   Zwet, T Van ^p   Janssen, J ^q   Pelsers, M ^q   De Waal, W ^r   Aalfs, G ^s   Kiewiet, J ^s   Sanders, P ^s   Buel Bruins, H Van ^t   Bokhoven Rombouts, C Van ^u   Cornelissen, P ^u   Kersten, M ^u   Ruitenbeek, C Van ^u   Molenaar, I ^u   Doorn, E ^c   Masthoff, L ^c   Pannekoek, E ^c   Sigurdsson, V ^c   Bugter, M ^v   Gotz H ^v   Illidge Onder De Linden, M ^v   Mattijssen, M ^v   Stam, J ^v   Swaders, E ^v   Groot, F De ^w   Postma, F ^w   Brouwers, E ^x   Niekamp, A ^x   Smit, M ^x   Botraby, A ^y   Bukasa, D ^y   Haan, C De ^y   Hut Van Vliet, P ^y   Taconis, T ^y   Graas, M De ^z   Hondelink, I ^z   Kampman, C ^z   Gelissen Hansen, A ^aa   Koning, I De ^aa   Kruchten, H Van ^aa   Pas, M Van De ^aa   Fennema, H ^ab   Heijman, T ^ab   Hogewoning, A ^ab   Leeuwen, A Van ^ab   Rooijen, M Van ^ab   Neienhuijsen, F ^ab   Pelgrim, M ^ab   more..

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^e South Limburg Public Health Service   (Netherlands)

^f Medical Microbiological Laboratories Certe   (Netherlands)

^g ETZ Hospital Tilburg   (Netherlands)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ Public Health Laboratory   (Netherlands)

^j University Medical Center   (Netherlands)

^k JEROEN BOSCH HOSPITAL   (Netherlands)

^l RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^m Izore   (Netherlands)

ⁿ Lab Mic TA   (Netherlands)

^o Isala   (Netherlands)

^p Rijnstate   (Netherlands)

^q Medical Laboratory Dr Stein and Collegae   (Netherlands)

^r CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^s Public Health Services   (Netherlands)

^t PHS IJsselland   (Netherlands)

^u PHS Gelderland Zuid   (Netherlands)

^v Rotterdam Rijnmond Police Department   (Netherlands)

^w PHS Groningen   (Netherlands)

^x PHS Fryslân   (Netherlands)

^y PHS Twente   (Netherlands)

^z PHS Hart voor Brabant   (Netherlands)

^aa Amsterdam   (Netherlands)

^ab PHS Gelderland Midden   (Netherlands)

more..

Author keywords

Cervarix; human papillomavirus; human papillomavirus vaccine; public health; vaccine effectiveness

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE, L1 TYPE 16, 18;

ADOLESCENT; ADULT; ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; CROSS PROTECTION; CROSS-SECTIONAL STUDY; DRUG EFFICACY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 19; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; MAJOR CLINICAL STUDY; MATHEMATICAL ANALYSIS; NONHUMAN; OBSERVATIONAL STUDY; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; SELF REPORT; UTERINE CERVIX CANCER; VACCINATION; VAGINAL SWAB; VIRUS DETECTION; VIRUS EXAMINATION; WART VIRUS; CLASSIFICATION; GENETICS; GENOTYPE; IMMUNOLOGY; ISOLATION AND PURIFICATION; NETHERLANDS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; TREATMENT OUTCOME; VAGINA; VIROLOGY; YOUNG ADULT;

ADOLESCENT; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPE; HUMANS; NETHERLANDS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TREATMENT OUTCOME; VAGINA; YOUNG ADULT;

EID: 85040552168     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jix582     Document Type: Article

References (44)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-9.
2. Bouvard V, Baan R, Straif K, et al.; WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens-Part B: Biological agents. Lancet Oncol 2009; 10:321-2.
3. de Sanjose S, Quint WG, Alemany L, et al.; Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11:1048-56.
4. Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: A synthetic analysis. Lancet Glob Health 2016; 4:e609-16.
5. Paavonen J, Naud P, Salmeron J, et al.; HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-14.
6. de Melker HE, Conyn-van Spaendonck MA, Boot HJ, Coutinho RA. [Introduction to vaccination against cervical cancer]. Ned Tijdschr Geneeskd 2009; 153:658-61.
7. Skinner SR, Apter D, De Carvalho N, et al. Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases. Expert Rev Vaccines 2016; 15:367-87.
8. Wheeler CM, Castellsagué X, Garland SM, et al.; HPV PATRICIA Study Group. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13:100-10.
9. Struyf F, Colau B, Wheeler CM, et al.; HPV PATRICIA Study Group. Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNA. Clin Vaccine Immunol 2015; 22:235-44.
10. Herrero R, Wacholder S, Rodríguez AC, et al.; Costa Rica Vaccine Trial Group. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov 2011; 1:408-19.
11. Woestenberg PJ, King AJ, van der Sande MA, et al.; Medical Microbiological Laboratories; Public Health Services. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors. J Infect 2017; 74:393-400.
12. Mollers M, King AJ, Knol MJ, et al. Effectiveness of human papillomavirus vaccine against incident and persistent infections among young girls: Results from a longitudinal Dutch cohort study. Vaccine 2015; 33:2678-83.
13. Cuschieri K, Kavanagh K, Moore C, Bhatia R, Love J, Pollock KG. Impact of partial bivalent HPV vaccination on vaccine-type infection: A population-based analysis. Br J Cancer 2016; 114:1261-4.
14. Kumakech E, Berggren V, Wabinga H, et al. Significantly reduced genoprevalence of vaccine-type HPV-16/18 infections among vaccinated compared to non-vaccinated young women 5.5 years after a bivalent HPV-16/18 vaccine (Cervarix® ) pilot project in Uganda. PLoS One 2016; 11:e0160099.
15. Kavanagh K, Pollock KG, Cuschieri K, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: A 7-year cross-sectional study [published online ahead of print 28 September, 2017]. Lancet Infect Dis. doi: 10.1016/S1473-3099(17)30468-1.
16. Pollock KG, Kavanagh K, Potts A, et al. Reduction of lowand high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer 2014; 111:1824-30.
17. Jit M, Chapman R, Hughes O, Choi YH. Comparing bivalent and quadrivalent human papillomavirus vaccines: Economic evaluation based on transmission model. BMJ 2011; 343:d5775.
18. Brisson M, Laprise JF, Drolet M, et al. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: A transmission-dynamic modeling study. Vaccine 2013; 31:3863-71.
19. Joura EA, Giuliano AR, Iversen OE, et al.; Broad Spectrum HPV Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015; 372:711-23.
20. Vriend HJ, Boot HJ, van der Sande MA; Medical Microbiological Laboratories; Municipal Health Services. Type-specific human papillomavirus infections among young heterosexual male and female STI clinic attendees. Sex Transm Dis 2012; 39:72-8.
21. Vriend HJ, Bogaards JA, van der Klis FR, et al.; Medical Microbiological Laboratories, Municipal Health Services. Patterns of human papillomavirus DNA and antibody positivity in young males and females, suggesting a site-specific natural course of infection. PLoS One 2013; 8:e60696.
22. Scherpenisse M, Mollers M, Schepp RM, et al. Seroprevalence of seven high-risk HPV types in The Netherlands. Vaccine 2012; 30:6686-93.
23. Woestenberg PJ, van Oeffelen AA, Stirbu-Wagner I, van Benthem BH, van Bergen JE, van den Broek IV. Comparison of STI-related consultations among ethnic groups in the Netherlands: An epidemiologic study using electronic records from general practices. BMC Fam Pract 2015; 16:70.
24. Auranen K, Rinta-Kokko H, Goldblatt D, et al.; Pneumococcal Carriage Group (PneumoCarr). Colonisation endpoints in Streptococcus pneumoniae vaccine trials. Vaccine 2013; 32:153-8.
25. Xue X, Gange SJ, Zhong Y, et al. Marginal and mixed-effects models in the analysis of human papillomavirus natural history data. Cancer Epidemiol Biomarkers Prev 2010; 19:159-69.
26. Halloran ME, Longini IM, Struchiner C. Design and analysis of vaccine studies. Statistics for biology and health. New York: Springer, 2010.
27. Lehtinen M, Paavonen J, Wheeler CM, et al.; HPV PATRICIA Study Group. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13:89-99.
28. Rondy M, van Lier A, van de Kassteele J, Rust L, de Melker H. Determinants for HPV vaccine uptake in the Netherlands: A multilevel study. Vaccine 2010; 28:2070-5.
29. Malagón T, Drolet M, Boily MC, et al. Cross-protective efficacy of two human papillomavirus vaccines: A systematic review and meta-analysis. Lancet Infect Dis 2012; 12:781-9.
30. Bogaards JA, Coupé VM, Xiridou M, Meijer CJ, Wallinga J, Berkhof J. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence. Epidemiology 2011; 22:505-15.
31. Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: Analysis of national sentinel surveillance data. Lancet Infect Dis 2011; 11:39-44.
32. Harrison C, Britt H, Garland S, et al. Decreased management of genital warts in young women in Australian general practice post introduction of national HPV vaccination program: Results from a nationally representative cross-sectional general practice study. PLoS One 2014; 9:e105967.
33. Smith MA, Liu B, McIntyre P, Menzies R, Dey A, Canfell K. Fall in genital warts diagnoses in the general and indigenous Australian population following implementation of a national human papillomavirus vaccination program: Analysis of routinely collected national hospital data. J Infect Dis 2015; 211:91-9.
34. van Lier EA, Oomen PJ, Giesbers H, Drijfhout IH, de Hoogh PAAM, de Melker HE. Vaccination coverage National Immunization Program the Netherlands, report year 2011 [in Dutch]. Bilthoven: RIVM, 2011.
35. van Lier EA, Oomen PJ, Giesbers H, et al. Vaccination coverage National Immunization Program the Netherlands, report year 2016 [in Dutch]. Bilthoven: RIVM, 2016.
36. van Lier EA, Oomen PJ, Giesbers H, Drijfhout IH, de Hoogh PAAM, de Melker HE. Vaccination coverage National Immunization Program the Netherlands, report year 2012 [in Dutch]. Bilthoven: RIVM, 2012.
37. de Araujo-Souza PS, Ramanakumar AV, Candeias JM, et al.; Ludwig-McGill Cohort Study. Determinants of baseline seroreactivity to human papillomavirus type 16 in the Ludwig-McGill cohort study. BMC Infect Dis 2014; 14:578.
38. Drolet M, Bénard É, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: A systematic review and meta-analysis. Lancet Infect Dis 2015; 15:565-80.
39. Cameron RL, Kavanagh K, Pan J, et al. Human papillomavirus prevalence and herd immunity after introduction of vaccination program, Scotland, 2009-2013. Emerg Infect Dis 2016; 22:56-64.
40. Mesher D, Panwar K, Thomas SL, Beddows S, Soldan K. Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: An ongoing cross-sectional study. BMJ Open 2016; 6:e009915.
41. van Alewijk D, Kleter B, Vent M, et al. A human papilloma virus testing algorithm comprising a combination of the L1 broad-spectrum SPF10 PCR assay and a novel E6 highrisk multiplex type-specific genotyping PCR assay. J Clin Microbiol 2013; 51:1171-8.
42. Labo Bio-medical Products. DNA ELISA kit HPV SPF10, version 1. Rijswijk: Labo Bio-medical Products BV, 2016.
43. van Doorn LJ, Molijn A, Kleter B, Quint W, Colau B. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol 2006; 44:3292-8.
44. Tota JE, Ramanakumar AV, Jiang M, et al. Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination. Am J Epidemiol 2013; 178:625-34.